Are Peptides Legal in Colorado? (2026)
Colorado at a glance
- State controlled-substances law
- Colo. Rev. Stat. § 18-18-101 et seq. (Uniform Controlled Substances Act of 2013); Schedule III at § 18-18-205 (codes.findlaw.com)
- Human growth hormone under state law
- Listed as a controlled substance in state law (C.R.S. § 18-18-102(3)(a)(X) and (XI); § 18-18-205(2)(e)) (codes.findlaw.com)
- Research peptides scheduled by the state
- Human growth hormone and hCG (treated as anabolic steroids, Schedule III) (C.R.S. § 18-18-102(3)(a)(X) and (XI); § 18-18-205(2)(e)) (codes.findlaw.com)
- Board of Pharmacy on compounded GLP-1s
- No statement located
- Medical board on peptide prescribing
- No statement located
- GLP-1 by telehealth
- Yes. C.R.S. § 12-240-107(1)(g) places telemedicine within the practice of medicine with no statutory in-person examination requirement. Colorado Medical Board policy holds telehealth to the in-person standard, requires Colorado licensure where the patient is located, and treats prescribing solely on an online questionnaire as unacceptable. (codes.findlaw.com)
- State-level enforcement, 2023 to 2026
- None found
- Last verified
- 28 September 2026, confidence medium
The federal rules that apply in Colorado, as everywhere
Federal law is the same in every state, and it is where almost all of the legal weight sits. Under the Federal Food, Drug, and Cosmetic Act a product intended to treat a condition or change how the body works is a drug, and an unapproved new drug cannot be introduced into interstate commerce. That rule binds the seller, not the buyer. The FDA's 2026 warning letters to research-peptide vendors say the same thing eleven times over: a "research use only" label does not help when the website, the bundled bacteriostatic water or a dosing calculator shows the product is meant for human use. The Bureau's enforcement tracker lists every letter, case and lawsuit with its source.
Three federal points matter for a reader in Colorado:
- Human growth hormone is the exception. 21 U.S.C. § 333(e) makes it a federal offence to distribute or possess somatropin for any use not approved by the Secretary of HHS. That statute covers HGH itself, not the secretagogues (sermorelin, ipamorelin, CJC-1295) that prompt the body's own release.
- Compounding is a separate track. A licensed pharmacy may only compound from bulk substances on the FDA's 503A list. BPC-157, TB-500, MOTS-c, KPV, Semax and Epitalon were moved to Category 2 in September 2023, removed from it in April 2026, and recommended for the list by the FDA's advisory committee on 23 and 24 July 2026. No rule has followed, so none of the six is on the list as of 31 October 2026. On 30 October 2026 HHS published an interim, non-binding policy (91 FR 68526) saying it does not intend to take enforcement action against a state-licensed pharmacy, federal facility or licensed physician that compounds one of these six under ten conditions, including a prescription for an individual patient. It is not an FDA approval, it gives research-use-only vials no cover, and Colorado's own pharmacy rules still apply. The policy explainer lists the ten conditions and the PCAC vote page has every tally.
- GLP-1 compounding is closing, not opening. The FDA has declared the semaglutide and tirzepatide shortages over, proposed in April 2026 to keep both off the 503B bulks list, and sent batches of letters to telehealth sellers in March and June 2026. Vials sold as "GLP-1 S" or "GLP-3 R" for research are unapproved new drugs in the FDA's view wherever the buyer lives.
What Colorado law adds
Colorado's controlled-substances law (Colo. Rev. Stat. § 18-18-101 et seq. (Uniform Controlled Substances Act of 2013); Schedule III at § 18-18-205) decides whether possessing a compound is a state offence. Peptides only become a state-law problem if they appear in those schedules or in a specific state ban. (codes.findlaw.com)
Compounds Colorado has scheduled or restricted
- Human growth hormone and hCG (treated as anabolic steroids, Schedule III) (C.R.S. § 18-18-102(3)(a)(X) and (XI); § 18-18-205(2)(e)) (codes.findlaw.com)
Human growth hormone
Colorado's definition of anabolic steroids expressly includes human chorionic gonadotropin and human growth hormone, and anabolic steroids are Schedule III, so unprescribed possession of HGH is a state controlled-substance offence as well as a federal one. (C.R.S. § 18-18-102(3)(a)(X) and (XI); § 18-18-205(2)(e)) (codes.findlaw.com)
Compounded semaglutide and tirzepatide
No Colorado Board of Pharmacy statement specific to compounded GLP-1 drugs was located. Licensed Colorado pharmacies follow the federal 503A and 503B rules, under which the shortage exception for semaglutide and tirzepatide has ended.
Clinics, medspas and prescribers
No Colorado medical board guidance specific to peptide therapy was located. A Colorado prescriber who administers BPC-157 or another unapproved peptide is exposed under the state's medical practice act and, since the FDA's 2026 letters, under federal law; the July 2026 advisory vote has not changed that yet.
Buying, possessing and using research peptides in Colorado
No Colorado provision on unscheduled research peptides was found, but human growth hormone and hCG are Schedule III in Colorado, so unprescribed possession of those is a state controlled-substance offence. (codes.findlaw.com)
Ordering from a vendor in another state. Almost every research-peptide order into Colorado is interstate commerce, which is exactly what the FDCA governs. The risk sits with the vendor: the FDA's letters name the seller, and Eli Lilly said in August 2026 it had referred more than 200 sellers to the FDA, the DOJ, state attorneys general and licensing boards. Connecticut's attorney general has already used state consumer-protection law against a "research grade" GLP-1 seller (2025), which is the template other states can copy. The Bureau's vendor scorecard notes which vendors publish batch testing; none of the scored vendors appears in the tracker as of September 2026.
GLP-1 drugs by prescription. Yes. C.R.S. § 12-240-107(1)(g) places telemedicine within the practice of medicine with no statutory in-person examination requirement. Colorado Medical Board policy holds telehealth to the in-person standard, requires Colorado licensure where the patient is located, and treats prescribing solely on an online questionnaire as unacceptable. (codes.findlaw.com) The branded pens are the only fully approved route; compounded versions are now on the wrong side of the FDA's shortage rules.
Sports and employment testing are not a Colorado law question. Growth hormone secretagogues and GHRH analogues are on the WADA Prohibited List everywhere; a standard workplace panel does not screen for peptides. The national legal guide covers both.
Not sure which of these you actually need?
Answer five questions about your goal, experience and budget and the Stack Builder shows you a matched research protocol on screen, with the compounds, cycle shape and vendor picks from the vendors we score.
Build your stack, 2 minutesEnforcement in Colorado
The Bureau found no Colorado-level action against a peptide seller, clinic or compounded-GLP-1 seller between 2023 and September 2026. Federal actions apply regardless of state; the enforcement tracker lists them.
Editor's note. SB 26-066, Regulation of Compounded Weight-Loss Medication (labelling, sourcing and per-dose fines), passed the Senate but was postponed indefinitely by the House health committee on 5 May 2026, so it is not law.
Frequently asked questions
Are peptide prescriptions available to residents of Colorado?
Yes for FDA-approved peptide drugs, such as semaglutide, tirzepatide, tesamorelin or bremelanotide: a prescriber licensed in Colorado, in person or by telehealth, can prescribe them. Compounded peptides are narrower. A 503A pharmacy may only compound from bulk substances that have a USP monograph, are a component of an FDA-approved drug, or are on the FDA's 503A bulks list, and BPC-157 and most wellness peptides meet none of those tests. Since 30 October 2026 an interim HHS policy says HHS does not intend to take enforcement action when a state-licensed pharmacy, federal facility or licensed physician compounds six of them (BPC-157, TB-500, MOTS-c, KPV, Semax and Epitalon) under ten conditions, including a prescription for an individual patient; the policy is not binding and is not an FDA approval.
Is BPC-157 legal in Colorado?
Colorado has not scheduled BPC-157, so possessing it is not an offence under Colorado law. Federally it is an unapproved new drug: selling it for human use is a violation by the seller, and licensed pharmacies cannot compound it because it is not on the 503A bulks list, despite the advisory committee's July 2026 recommendation. Research vendors sell it under a research-use-only label, which the FDA's 2026 letters treat as no defence when the site shows human use.
Can I get semaglutide or tirzepatide by telehealth in Colorado?
Yes. C.R.S. § 12-240-107(1)(g) places telemedicine within the practice of medicine with no statutory in-person examination requirement. Colorado Medical Board policy holds telehealth to the in-person standard, requires Colorado licensure where the patient is located, and treats prescribing solely on an online questionnaire as unacceptable. Compounded versions are no longer covered by the FDA's shortage exception, and the FDA has proposed keeping semaglutide and tirzepatide off the 503B bulks list, so expect availability of compounded product to keep shrinking.
Is HGH legal in Colorado?
Only with a valid prescription. Colorado lists human growth hormone as a controlled substance and federal law, 21 U.S.C. section 333(e), separately makes distribution or possession for a non-approved use a federal offence. Sermorelin, ipamorelin and CJC-1295 are not HGH and fall under the general unapproved-drug rules instead.
Is it legal to sell peptides in Colorado?
Selling an unapproved peptide for human use breaks the federal Food, Drug, and Cosmetic Act wherever the seller is, Colorado included, and that applies online and in a store. Research vendors sell under a research-use-only label; the FDA's 2026 warning letters treat that label as no defence when the site markets human use. Colorado adds its own rules on at least one compound, see the state-law section above.
Sources
- https://codes.findlaw.com/co/title-18-criminal-code/co-rev-st-sect-18-18-205/
- https://codes.findlaw.com/co/title-18-criminal-code/co-rev-st-sect-18-18-102/
- https://codes.findlaw.com/co/title-12-professions-and-occupations/co-rev-st-sect-12-240-107.html
Every Colorado fact above was checked against the linked source on 28 September 2026. If a statute or board position has changed, email [email protected] with the link and the page will be corrected and dated.